Literature DB >> 26250758

Recursive partitioning analysis of prognostic factors in post-transplant lymphoproliferative disorders (PTLD): a 120 case single institution series.

Francesca Montanari1, Dejan Radeski2, Venkatraman Seshan3, Bachir Alobeid4, Govind Bhagat4, Owen A O'Connor2.   

Abstract

The post-transplant lymphoproliferative disorders (PTLD) comprise a heterogeneous group of lymphocytic and plasma cell proliferations occurring in recipients of tissue allografts in the setting of immunosuppression. We describe our experience of 120 patients with PTLD seen between 1990 and 2009, one of the largest series reported by a single institution. Post-transplant lymphoproliferative disorders characteristics were analysed with regard to paediatric and adult patients, and with regard to the decade of diagnosis, 1990-1999 (pre-rituximab era) versus 2000-2009 (the rituximab era). We present a new prognostic score using the recursive partitioning model, consisting of the Eastern Cooperative Oncology Group (ECOG) score (0-1 vs. 2-4), age [paediatrics (<16 years old), adults (16-60 years old) and elderly (>60 years old)] and CD20 status (positive vs negative); separating patients into 4 risk categories based on overall survival. Low-risk included paediatric patients with ECOG score of 0-1; intermediate-low-risk included adults aged 16-60 years with an ECOG score of 0-1; intermediate-high-risk included elderly patients with an ECOG score 0-1 or paediatric patients and adults aged 16-60 years with an ECOG score of 2-4 and CD20 positive; high-risk group included patients of any age with an ECOG score of 2-4 and CD20 negative, and elderly patients with an ECOG score of 2-4 with CD20-positive PTLD.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  adult; paediatric; post-transplant lymphoproliferative disorders; prognostic factors; recursive partitioning analysis

Mesh:

Substances:

Year:  2015        PMID: 26250758     DOI: 10.1111/bjh.13621

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Post-transplant lymphoproliferative disorder in paediatric patients: the Irish perspective-a single centre experience.

Authors:  A Malone; G Kennedy; L Storey; A O'Marcaigh; M McDermott; A M Broderick; O P Smith
Journal:  Ir J Med Sci       Date:  2016-02-29       Impact factor: 1.568

2.  Comparison of Post-Transplantation Lymphoproliferative Disorder Risk and Prognostic Factors between Kidney and Liver Transplant Recipients.

Authors:  Krzysztof Mucha; Rafał Staros; Bartosz Foroncewicz; Bogna Ziarkiewicz-Wróblewska; Maciej Kosieradzki; Sławomir Nazarewski; Beata Naumnik; Joanna Raszeja-Wyszomirska; Krzysztof Zieniewicz; Leszek Pączek
Journal:  Cancers (Basel)       Date:  2022-04-13       Impact factor: 6.575

Review 3.  Joining Efforts for PTLD: Lessons Learned from Comparing the Approach and Treatment Strategies Across the Pediatric and Adult Age Spectra.

Authors:  Francesca Montanari; Manuela Orjuela-Grimm
Journal:  Curr Hematol Malig Rep       Date:  2021-02-05       Impact factor: 3.952

4.  Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients.

Authors:  Rohit Bishnoi; Ravneet Bajwa; Aaron J Franke; William Paul Skelton; Yu Wang; Niraj M Patel; William Birdsall Slayton; Fei Zou; Nam H Dang
Journal:  Exp Hematol Oncol       Date:  2017-09-29

5.  Characteristics, management, and outcome of pediatric patients with post-transplant lymphoproliferative disease-A 20 years' experience from Austria.

Authors:  Anna Füreder; Gabriele Kropshofer; Martin Benesch; Michael Dworzak; Sabine Greil; Wolf-Dietrich Huber; Holger Hubmann; Anita Lawitschka; Georg Mann; Ina Michel-Behnke; Thomas Müller-Sacherer; Herbert Pichler; Ingrid Simonitsch-Klupp; Wolfgang Schwinger; Zsolt Szepfalusi; Roman Crazzolara; Andishe Attarbaschi
Journal:  Cancer Rep (Hoboken)       Date:  2021-03-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.